Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer

Cancer

Volumn 118, Issue 19, 2012, Pages 4652-4659

  Dawood, Shaheenah ^a   Lei, Xiudong ^b   Litton, Jennifer K ^b   Buchholz, Thomas A ^b   Hortobagyi, Gabriel N ^b   Gonzalez Angulo, Ana M ^b  

^a DUBAI HOSPITAL   (United Arab Emirates)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INCIDENCE; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84866482392     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27434     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Lu J, Steeg PS, Price JE, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009; 69: 4951-4953.
3. Lin NU, Bellon JR, Winer EP,. CNS metastases in breast cancer. J Clin Oncol. 2004; 22: 3608-3617.
4. Tsukada Y, Fouad A, Pickren JW, Lane WW,. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983; 52: 2349-2354.
5. Patanaphan V, Salazar OM, Risco R,. Breast cancer: metastatic patterns and their prognosis. South Med J. 1988; 81: 1109-1112.
6. Leyland-Jones B,. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009; 27: 5278-5286.
7. Pelletier EM, Amonkar MM, Shim B,. Incidence and prevalence of brain metastases among patients with advanced breast cancer in a US managed-care population. J Clin Oncol. 2007; 25 (suppl 18): 353s. Abstract 6624.
8. Carey LA, Ewend MG, Metzger R, et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat. 2004; 88: 273-280.
9. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A,. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002; 94: 2698-2705.
10. Perou CM, SAørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
11. SAørlie T,. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004; 40: 2667-2675.
12. SAørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874.
13. Brenton JD, Carey LA, Ahmed AA, Caldas C,. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005; 23: 7350-7360.
14. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW,. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer. 2008; 112: 2359-2367.
15. Dawood SS, Broglio K, Esteva FJ, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008; 19: 1242-1248.
16. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP,. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008; 113: 2638-2645.
17. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13: 2329-2334.
18. Graesslin O, Abdulkarim BS, Coutant C, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol. 2010; 28: 2032-2037.
19. Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009; 20: 621-627.
20. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003; 83: 803-819.
21. The World Health Organization Histological Typing of Breast Tumors-Second Edition. The World Organization. Am J Clin Pathol. 1982; 78: 806-816.
22. Black MM, Speer FD,. Nuclear structure in cancer tissues. Surg Gynecol Obstet. 1957; 105: 97-102.
23. Gray B,. The cmprsk package [computer program]. Vienna, Austria: The Comprehensive R Archive Network, Vienna University of Economics and Business Administration; 2007. http://www.r-project.org
24. Pestalozzi BC, Zahrieh D, Price KN, et al. International Breast Cancer Study Group (IBCSG). Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006; 17: 935-944.
25. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK 5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006; 30: 1097-1104.
26. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R,. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006; 107: 696-704.
27. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V,. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006; 15: 219-225.
28. Samaan NA, Buzdar AU, Aldinger KA, et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981; 47: 554-560.
29. Heitz F, Harter P, Traut A, Lueck HJ, Beutel B, du Bois A,. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. J Clin Oncol. 2008; 26 (suppl): abstract 1010.
30. Nam BH, Kim SY, Han HS, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008; 10: R20.
31. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A,. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol. 2008; 19: 1561-1565.
32. Dawood S, Broglio K, Esteva FJ, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008; 19: 1242-1248.
33. Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011; 117: 1602-1611.
34. O'Brien KM, Cole SR, Tse CK, et al. Intrinsic breast tumor subtypes, race, and long-Term survival in the Carolina Breast Cancer Study. Clin Cancer Res. 2010; 16: 6100-6110.
35. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-Term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26: 1275-1281.
36. Carey LA,. Directed therapy of subtypes of triple-negative breast cancer. Oncologist. 2011; 16 (suppl 1): 71-78.
37. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14: 1368-1376.
38. Perou CM,. Molecular stratification of triple-negative breast cancers. Oncologist. 2011; 16 (suppl 1): 61-70.